Immunotherapeutic Vaccine to Combat Type 1 Diabetes in Final Stage of Clinical Development

The development of an immunotherapeutic vaccine to combat type 1 diabetes is well on track and clinical trials are at a final stage at the Harvard University, Dr Sotiris Adamidis, Professor at the University of Athens and President of the European Society of Diabetes, Metabolic Syndrome and Obesity, said in an interview with Praktoreio 104.9 FM.

On the occasion of the 4th Panhellenic Conference of the European Society of Diabetes, Metabolic Syndrome and Obesity held at the Zappeion Mansion, Adamidis explained to the radio station of the Athens-Macedonian News Agency (ANA) how cancer is associated with obesity and cited the reasons why obese people are susceptible to cancer.

More specifically, he explained that there are metabolic processes that have to do with the obesity toxicity at cellular level, ie the amount of oxidants and a reduction in antioxidant protection. However, these cases can be treated at an early stage, very effectively, by changing the lifestyle and especially body weight, and correcting the parameters of the metabolic syndrome.

He also said that high bad cholesterol is related to cardiovascular risk and stressed that simple blood tests may not be sufficient. “According to statistics, 50 pct of strokes in the US occur to people with normal cholesterol values,” he said.
(Source: AMNA)